Form 4: Rapport Therapeutics Insider Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Third Rock Ventures V, L.P. and 5 others reported changes in beneficial ownership of Rapport Therapeutics, Inc. common stock on October 30, 2026.

Summary

  • Grant/award: acquired 238,095 Common Stock at $21.00 ($4,999,995) on October 30, 2026; holds 6,518,620 after (Direct).
  • Grant/award: acquired 1,190,476 Common Stock at $21.00 ($24,999,996) on October 30, 2026; holds 2,159,694 after (Indirect).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Third Rock Ventures V, L.P. — Director, 10% owner

Third Rock Ventures GP V, LP — Director, 10% owner

Trv Gp V, Llc — Director, 10% owner

Third Rock Ventures VI, L.P. — Director, 10% owner

Third Rock Ventures GP VI, L.P. — Director, 10% owner

Trv Gp Vi, Llc — Director, 10% owner

DateTransactionSecuritySharesPriceValueHeld After
2026-10-30Grant/awardCommon Stock238,095$21$5.0M6,518,620
2026-10-30Grant/awardCommon Stock1,190,476$21$25.0M2,159,694

Key Dates

DateDescription
2026-10-30Grant/award (238,095 shares)
2026-10-30Grant/award (1,190,476 shares)

Keywords

insider transaction, Form 4, RAPP, Rapport Therapeutics, Inc., neutral, Third Rock Ventures V, L.P., Third Rock Ventures GP V, LP, Trv Gp V, Llc, Third Rock Ventures VI, L.P., Third Rock Ventures GP VI, L.P., Trv Gp Vi, Llc

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.